New classificati on of Ph negative chronic myeloproliferative ne oplasi as


Authors: J. Kujíčková;  M. Do ubek
Authors‘ workplace: Interní hemato onkologická klinika Lékařské fakulty MU a FN Brno, pracoviště Bohunice, přednosta prof. MU Dr. Jiří Vorlíček, CSc.
Published in: Vnitř Lék 2009; 55(Suppl 1)(Supplementum 1): 23-28

Overview

New classificati on of Ph negative chronic myeloproliferative ne oplasi as starts from the previ o us classificati on of the World He alth Organizati on from 2001. New evidence in molecular bi ology and new vi ews of histopathological evalu ati on were the stimuli for the current revisi on of classificati on. The revi ew introduces current classificati on criteri a of Ph negative myeloproliferative ne oplasi as.

Key words:
Ph negative chronic myeloproliferative ne oplasi as –  classificati on


Sources

1. Swerdlow SH, Campo E, Hartus NL et al. WHO Classificati on of Tumo urs of Haematopo i etic and Lympho id Tissues. Lyon: IARC Press 2008.

2. Adam Z, Vorlíček J, Vaníček J et al. Di agnostické a léčebné postupy u maligních chorob. Druhé, aktu alizované a doplněné vydání. Praha: Grada Publishing 2004.

3. Jemal A, Tiwari RC, Murray T et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 8– 29.

4. Kralovics R, Passamonti F, Buser AS et al. A gain‑of- uncti on mutati on of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779– 1790.

5. Baxter EJ, Scott LM, Campbell PJ et al. Aquired mutati on of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054– 1061.

6. Levine RL, Wadleigh M, Co ols J et al. Activating mutati on in the tyrosine kinase JAK2 in polycythemi a vera, essenti al thrombocythemi a, and myelo id metaplasi a with myelofibrosis. Cancer Cell 2005; 7: 387– 397.

7. James C, Ugo V, Le Co uédic JP et al. A unique clonal JAK2 mutati on le ading to constitutive signalling ca use of polycythemi a vera. Nature 2005; 434: 1144– 1148.

8. Zhao R, Xing S, Li Z et al. Identificati on of an acquired JAK2 mutati on in polycythemi a vera. J Bi ol Chem 2005; 280: 22788– 22792.

9. Levine RL, Lori a ux M, Huntly BJ et al. The JAK2V617F activating mutati on occurs in chronic myelomonocytic le ukemi a and acute myelo id le ukemi a, but not in acute lymphoblastic le ukemi a or chronic lymphocytic le ukemi a. Blo od 2005; 106: 3377– 3379.

10. Remacha AF, Nomdedéu JF, Puget G et al. Occurence of the JAK2 V617F mutati on in the WHO provisi onal entity: myelodysplastic/ myeloproliferative dise ase, unclassifi able- refractory anemi a with ringed sideroblasts associ ated with marked thrombocytosis. Haematologica 2006; 91: 719– 720.

11. Szpurka H, Ti u R, Murugesan G et al. Refractory anemi a with ringed sideroblasts associ ated with marked thrombocytosis (RARS-T), another myeloproliferative conditi on characterized by JAK2 V617F mutati on. Blo od 2006; 108: 2173– 2181.

12. Scott LM, Tong W, Levine RL et al. JAK2 exon 12 mutati ons in polycythemi a vera and idi opatic erytrocytosis. N Engl J Med 2007; 356: 459– 468.

13. Pardanani AD, Levine RL, LaSho TL et al. MPL515 mutati ons in myeloproliferative and other myelo id disorders: a study of 1182 pati ents. Blo od 2006; 108: 3472– 3476.

14. Yo u W, Weisbrot IM. Chronic ne utrophilic le ukaemi a. Report of two cases and rewi ew of the literature. Am J Clin Pathol 1979; 72: 233– 242.

15. Marchi oli R, Finazzi G, Landolfi R et al. Vascular and ne oplastic risk in large cohort of pati ents with polycythemi a vera. J Clin Oncol 2005; 23: 2224– 2232.

16. Andri e ux JL, Demory JL. Karyotype and molecular cytogenetic studi es in polycythemi a vera. Curr Hematol Rep 2005; 4: 224– 229.

17. Andréasson B, Swolin B, Kutti J et al. Pati ents with idi opathic myelofibrosis show incre ased CD34+ cell concentrati ons in peripheral blo od compared to pati ents with polycythaemi a vera and essenti al thrombocythaemi a. Eur J Haematol 2002; 68: 189– 193.

18. Cervantes F, Dupri ez B, Pereira A et al. New prognostic scoring system for primary myelofibrosis based on a study of the Internati onal Gro up for Myelofibrosis Rese arch and Tre atment. Blo od 2009; 113: 2895– 2901.

19. Finazzi G, Harrison C. Essenti al thrombocythaemi a. Semin Hematol 2005; 42: 230– 238.

20. Tefferi A, Pardanani A. Clinical, genetic, and therape utic insights into systemic mast cell dise ase. Curr Opin Hematol 2004; 11: 58– 64.

21. Brunning RD, McKenna RW, Rossai J et al. Systemic mastocytosis. Extracutane o us manifestati ons. Am J Surg Pathol 1983; 7: 425– 438.

22. Tefferi A, Patnaik MM, Pardanani A. Eosinophili a: secondary, clonal and idi opatic. Br J Haematol 2006; 133: 468– 492.

Labels
Diabetology Endocrinology Internal medicine

Article was published in

Internal Medicine

Issue Supplementum 1

2009 Issue Supplementum 1

Most read in this issue

This topic is also in:


Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account